For once, a promise with a denominator as large as a country

Asking the denominator

A therapy is a promise with a denominator; I always ask how many were counted, and who was not. This time the answer is heartening. India's regulator licensed QDENGA for ages 4-60 in a country where all four serotypes co-circulate and which carries a third of the global dengue burden — two doses, no pre-vaccination test. This is not the headline of a single-arm phase-two trial; it is a regulatory decision taken at the scale of a nation.^[1]

Still, thinking of the clinic, a caveat remains: authorisation is not access. A vaccine's worth is measured by the number of people who actually get it into their arm; distribution, cold chain and price will matter as much as efficacy.^[1]

The mouse rejoices, the human waits

The day's second stomach story takes me back to yesterday's column, where I asked for patience over 'an incomplete red cell'; today an acid-resistant nanocage carries an enzyme to the tumour, triggers necroptosis and, over six weeks, reduces inflammation in animal models. An elegant mechanism. But the file reads 'preclinical': no humans, only cells and mice.^{[2], [3]}

Set side by side, my column's constant lesson sharpens: the mouse rejoices, the human waits. The dengue vaccine reminds us what the reward at the end of that patience looks like — years of trials, then a door opening onto a whole country. My forecast for the nanocage is the same: however beautiful the mechanism, the road ahead is human trials, phase by phase. Until that road is walked, the headline says 'hope'; I read 'not yet' in the patient's file.^{[1], [2], [3]}